The Carlyle Group Agrees To Acquire Johnson & Johnson’s Ortho-Clinical Diagnostics For $4.15 Billion
Global alternative asset manager
Carlyle Group (NASDAQ:CG) has agreed to acquire Johnson & Johnson’s
Ortho-Clinical Diagnostics (OCD) business, a global provider of
solutions for screening, diagnosing,...
Global alternative asset manager The Carlyle Group (NASDAQ:CG) has agreed to acquire Johnson & Johnson’s Ortho-Clinical Diagnostics (OCD) business, a global provider of solutions for screening, diagnosing, monitoring and confirming diseases, for $4.15 billion. The transaction is subject to customary regulatory approvals and is expected to close in the middle of 2014. Stephen H. Wise, Managing Director of The Carlyle Group, said, “Ortho-Clinical Diagnostics is an established global brand with a reputation for quality and innovation. Through accelerated investment in research and product development and continued expansion into both emerging and established markets, we expect to tap into rising demand for sophisticated medical diagnostic products and services worldwide. We have been focused on the diagnostics industry for many years given its attractive growth prospects, driven by the crucial role it plays in health care decision-making and influencing patient outcomes. We believe that OCD, with its world class employee base and talented management team, is poised for the next level of success.” Eric Compton, Worldwide President, Ortho-Clinical Diagnostics, said, “We are excited to work with Carlyle and believe OCD will be well-positioned as an independent company focused exclusively on the in vitro diagnostics market. In combination with Carlyle’s global reach and deep experience in the healthcare sector, OCD will have the opportunity to invest in new, innovative products and services for its customers and provide an environment for its professionals to excel in a competitive global marketplace.” Headquartered in Raritan, NJ, with manufacturing operations in Rochester, NY, Pompano Beach, FL and Pencoed, Wales, OCD operates in 130 countries. OCD serves clinical laboratories and the transfusion medicine community around the world. The company is a provider of total solutions for early screening, diagnosing, monitoring and confirming diseases, focused on supporting hospitals, laboratories and blood centers worldwide. Equity for the transaction comes from Carlyle Partners VI, a $13 billion U.S. Buyout fund, which completed fundraising in November 2013 with two hundred sixty-nine investors from 43 countries.